The Effectiveness of rTMS in Depressed VA Patients
Trial ID or NCT#
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
CSP #556 - The Effectiveness of rTMS in Depressed VA Patients
- - Between 18 and 80 years of age
- - Using the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM) Disorders (SCID) for DSM-IV-TR (First et al. 2002) patients will be diagnosed Major Depressive Disorder (MDD).
- - Have a Hamilton Rating Scale for Depression (HRSD-24) score greater or equal to 20 no more than 7 days prior to randomization.
- - Exhibit moderate level of resistance to antidepressant treatment defined, using the Antidepressant Treatment History Form (ATHF) (Sackeim et al. 1990), as failure of at least two adequate medication trials.
- - Duration of current episode of less than or equal to 10 years.
- - Ability to obtain a Motor Threshold (MT) (should be determined at the end of the screening process).
- - Currently under the care of a VA psychiatrist.
- - If on a psychotropic medication regimen, that regimen will be stable for at least 4 weeks prior to randomization and patient will be willing to remain on a stable regimen during the acute treatment phase.
- - Has an adequately stable condition and environment to enable attendance at scheduled clinic visits.
- - For female participants, agrees to use one of the following acceptable methods of birth control
- - Complete abstinence (not having sexual intercourse with anyone)
- - An oral contraceptive (birth control pills)
- - Norplant
- - Depo-Provera
- - A condom with spermicide
- - A cervical cap with spermicide
- - A diaphragm with spermicide
- - An Intrauterine device
- - Surgical sterilization (having tubes tied)
- - Able to read, verbalize understanding and voluntarily sign the Informed Consent Form prior to performance of any study-specific procedures or assessments.
- - Pregnant or lactating female (This is an FDA-required exclusion. In the future, if rTMS becomes a proven treatment for major depression, its safety in the context of pregnancy should be studied separately (Nahas et al. 1999).
- - Unable to be safely withdrawn, at least two-weeks prior to treatment commencement, from medications that substantially increase the risk of having seizures. For the purpose of this study, those medications are listed in Appendix G (for example, theophylline).
- - Have a cardiac pacemaker.
- - Have an implanted device (deep brain stimulation) or metal in the brain.
- - Have a cochlear implant.
- - Have a mass lesion, cerebral infarct, increased intracranial pressure, or other active central nervous system (CNS) disease, including a seizure disorder.
- - Known current psychosis as determined by DSM-IV or SCID (axis I, psychotic disorder, schizophrenia) or a history of a non-mood psychotic disorder.
- - Known current Bipolar I disorder as determined by SCID or a History of Bipolar I disorder.
- - Current amnestic disorders, dementia, Blessed Orientation-Memory-Concentration (BOMC) greater than 10, delirium, or other cognitive disorders.
- - Current substance abuse (not including caffeine or nicotine) as determined by positive toxicology screen, or by history via SCID, within 3 months prior to screening.
- - Patients with an elevated risk of seizure due to traumatic brain injury (TBI).
- - Participation in another concurrent clinical trial.
- - Patients with prior exposure to rTMS.
- - Active current suicidal intent or plan as evidenced by a score of 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS) or the endorsement of an actual attempt, interrupted attempt, or an aborted attempt in the past 6 months. All patients will be required to establish a written safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial (See Section X.B.8).
- - Unstable cardiac disease or recent (< 3 months previous) myocardial infarction.
- - Patient refuses to sign consent for participation in the study.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToRebecca Lenox
Go Back To The Trial